Fulvestrant
Hormonal antineoplastic drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Fulvestrant?
Summarize this article for a 10 year old
Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy.[2] It is given by injection into a muscle.[3]
Clinical data | |
---|---|
Pronunciation | /fʊlˈvɛstrənt/ fuul-VES-trənt |
Trade names | Faslodex, others |
Other names | ICI-182780; ZD-182780; ZD-9238; 7α-[9-[(4,4,5,5,5-Pentafluoropentyl)-sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17β-diol |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Intramuscular injection |
Drug class | Antiestrogen |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Low[1] |
Protein binding | 99%[1] |
Metabolism | Hydroxylation, conjugation (glucuronidation, sulfation)[1] |
Elimination half-life | IMTooltip Intramuscular injection: 40–50 days[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.170.955 |
Chemical and physical data | |
Formula | C32H47F5O3S |
Molar mass | 606.78 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Fulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved.[4] It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.[4]
Fulvestrant was approved for medical use in the United States in 2002.[5]